PubMed中文版

检索结果 16466
原始关键字 皮肤干燥 or 干燥皮肤 
转化关键字 ((((TITLE_ABS:("dry skin" or "dry skin")) OR (KW:("dry skin" or "dry skin"))) AND SRC:MED) AND SRC:MED) sort_cited:y 


影响因子

出版日期
文献类型
物种
PubMed ID 32203698
发表日期 2020-03-20
作者 Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, Féliz L, Vogel A.
文献标题 Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
原始出处 Lancet Oncol
影响因子 35.9   期刊引文指标 8.68

PubMed ID 30779531
发表日期 2019-02-16
作者 Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H, Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK.
文献标题 Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 29442540
发表日期 2018-02-14
作者 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, National Comprehensive Cancer Network.
文献标题 Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
原始出处 J Clin Oncol
影响因子 41.9   期刊引文指标 6.68

PubMed ID 28734759
发表日期 2017-07-19
作者 Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T.
文献标题 Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
原始出处 Lancet Oncol
影响因子 35.9   期刊引文指标 8.68

PubMed ID 27999003
发表日期 2017-01-01
作者 Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D.
文献标题 Diabetic Neuropathy: A Position Statement by the American Diabetes Association.
原始出处 Diabetes Care
影响因子 16.6   期刊引文指标 4.44

PubMed ID 27959700
发表日期 2016-12-06
作者 Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA, AURA3 Investigators.
文献标题 Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 27718784
发表日期 2016-10-08
作者 Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.
文献标题 Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 26115796
发表日期 2015-06-23
作者 Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.
文献标题 Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
原始出处 Lancet Oncol
影响因子 35.9   期刊引文指标 8.68

PubMed ID 26028255
发表日期 2015-05-30
作者 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA.
文献标题 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 25693012
发表日期 2015-02-01
作者 Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group.
文献标题 Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 25601342
发表日期 2015-01-16
作者 Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
文献标题 Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
原始出处 Lancet Oncol
影响因子 35.9   期刊引文指标 8.68

PubMed ID 25428504
发表日期 2014-11-01
作者 Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.
文献标题 Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
原始出处 Nature
影响因子 48.5   期刊引文指标 11.12

PubMed ID 23589827
发表日期 2013-04-01
作者 Günzel D, Yu AS.
文献标题 Claudins and the modulation of tight junction permeability.
原始出处 Physiol Rev
影响因子 28.7   期刊引文指标 5.48

PubMed ID 22149875
发表日期 2011-12-07
作者 Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, CLEOPATRA Study Group.
文献标题 Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 21449784
发表日期 2011-03-01
作者 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators.
文献标题 Boceprevir for previously treated chronic HCV genotype 1 infection.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 21306238
发表日期 2011-02-01
作者 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
文献标题 Everolimus for advanced pancreatic neuroendocrine tumors.
原始出处 N Engl J Med
影响因子 78.5   期刊引文指标 23.3

PubMed ID 20516446
发表日期 2010-06-01
作者 Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.
文献标题 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
原始出处 J Clin Oncol
影响因子 41.9   期刊引文指标 6.68

PubMed ID 19487381
发表日期 2009-06-01
作者 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.
文献标题 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
原始出处 J Clin Oncol
影响因子 41.9   期刊引文指标 6.68

PubMed ID 17493201
发表日期 2007-05-01
作者 Inouye SK, Studenski S, Tinetti ME, Kuchel GA.
文献标题 Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept.
原始出处 J Am Geriatr Soc
影响因子 4.5   期刊引文指标 1.27

PubMed ID 12716821
发表日期 2003-05-01
作者 Vinik AI, Maser RE, Mitchell BD, Freeman R.
文献标题 Diabetic autonomic neuropathy.
原始出处 Diabetes Care
影响因子 16.6   期刊引文指标 4.44